Search Results - "Tayal, Upasana"

Refine Results
  1. 1

    Genetics and genomics of dilated cardiomyopathy and systolic heart failure by Tayal, Upasana, Prasad, Sanjay, Cook, Stuart A

    Published in Genome medicine (22-02-2017)
    “…Heart failure is a major health burden, affecting 40 million people globally. One of the main causes of systolic heart failure is dilated cardiomyopathy (DCM),…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy by Tayal, Upasana, BMBCh, Newsome, Simon, MSc, Buchan, Rachel, MSc, Whiffin, Nicola, PhD, Walsh, Roddy, MSc, Barton, Paul J., PhD, Ware, James S., PhD, Cook, Stuart A., PhD, Prasad, Sanjay K., MD

    “…Dilated cardiomyopathy (DCM) has a population prevalence of ~1 in 500 and is associated with prognostically adverse arrhythmias at initial disease presentation…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Myocardial remodelling and recovery in dilated cardiomyopathy by Tayal, Upasana, Prasad, Sanjay K

    Published in JRSM Cardiovascular Disease (01-01-2017)
    “…Myocardial reverse remodeling has been reported to occur in 25–70% of patients with dilated cardiomyopathy. It is not yet fully understood whether remodeling…”
    Get full text
    Book Review Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Direct and indirect effect of the COVID-19 pandemic on patients with cardiomyopathy by Hammersley, Daniel J, Buchan, Rachel J, Lota, Amrit S, Mach, Lukas, Jones, Richard E, Halliday, Brian P, Tayal, Upasana, Meena, Devendra, Dehghan, Abbas, Tzoulaki, Ioanna, Baksi, A John, Pantazis, Antonis, Roberts, Angharad M, Prasad, Sanjay K, Ware, James S

    Published in Open heart (01-01-2022)
    “…Objectives(1) To evaluate the prevalence and hospitalisation rate of COVID-19 infections among patients with dilated cardiomyopathy (DCM) and hypertrophic…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15

    Urinary drug metabolite testing in chronic heart failure patients indicates high levels of adherence with life‐prolonging therapies by Sweeney, Mark, Cole, Graham D., Pabari, Punam, Hadjiphilippou, Savvas, Tayal, Upasana, Mayet, Jamil, Chapman, Neil, Plymen, Carla M.

    Published in ESC Heart Failure (01-06-2021)
    “…Aims Despite medical therapy for heart failure (HF) having proven benefits of improving quality of life and survival, many patients remain under‐treated. This…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20